Skip to main content
Top
Published in: CNS Drugs 4/2010

01-04-2010 | Original Research Article

For What Diagnoses Are Psychotropic Medications Being Prescribed?

A Nationally Representative Survey of Physicians

Author: Dr Tami L. Mark

Published in: CNS Drugs | Issue 4/2010

Login to get access

Abstract

Background: Psychoactive medications, such as antidepressants, are one of the most widely prescribed categories of drugs in the US; yet few studies have comprehensively examined the conditions for which psychoactive medications are prescribed. To our knowledge, no prior study has examined the extent to which psychoactive medications are prescribed for non-psychiatric somatic illnesses or the main types of psychiatric disorders for which psychoactive medications are being used.
Objective: To examine the diagnoses for which psychiatric medications are being prescribed in the US by analysing data from a nationally representative survey of physicians.
Methods: The data were obtained from the 2005 National Disease and Therapeutic Index (NDTI), a continuing survey of a US office-based panel of physicians. The 2005 physician panel consisted of approximately 4000 physicians reporting quarterly, which was projected to a universe of 500 722 physicians. The study focused on the diagnoses that were given as the primary reason for prescribing the following types of psychotropic medications: anti-depressants, antipsychotics and anti-anxiety medications.
Results: Of the total number of antidepressant drug mentions, 92.7% were prescribed for psychiatric conditions. The most common (65.3%) were mood disorders (e.g. depression), followed by anxiety disorders (16.4%), which together comprised 81.7% of all antidepressant drug mentions. Of the total number of anti-anxiety drug mentions, 67.7% were prescribed for psychiatric conditions. The most common diagnosis was anxiety disorders (comprising 39.6% of all drug mentions), followed by mood disorders (comprising 18.9% of all drug mentions). Almost one-third of anxiety medication drug mentions were for non-psychiatric conditions or conditions of unspecified type. Of the total number of antipsychotic drug mentions, 98.9% were prescribed for psychiatric conditions. The most common diagnoses, comprising 39.0% of all drug mentions, were mood disorders such as depression and bipolar disorder. The second most common psychiatric diagnosis was schizophrenia or other psychotic disorders, comprising 34.5% of drug mentions. Approximately 7.4% of drug mentions were for delirium, dementia, amnestic or other cognitive disorders. Attention-deficit/conduct/disruptive behaviour disorders were the diagnoses indicated on 5.7% of all antipsychotic drug mentions. Anxiety disorders were indicated on 5.5% of antipsychotic drug mentions. Disorders usually diagnosed in infancy/childhood/adolescence (e.g. autism) comprised 2.3% of antipsychotic drug mentions.
Conclusions: This research provides a broad view of the nature of psycho-active medication prescribing, which may serve as a guide to future research, policy and education about these medications, their perceived benefits and risks, and their uses.
Literature
2.
go back to reference Mark TL, Levit KR, Buck JA, et al. Mental health treatment expenditure trends, 1986–2003. Psychiatr Serv 2007 Aug; 58(8): 1041–8PubMedCrossRef Mark TL, Levit KR, Buck JA, et al. Mental health treatment expenditure trends, 1986–2003. Psychiatr Serv 2007 Aug; 58(8): 1041–8PubMedCrossRef
3.
go back to reference Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff (Millwood) 2005 Jan–Feb; 24(1): 195–205CrossRef Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff (Millwood) 2005 Jan–Feb; 24(1): 195–205CrossRef
4.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
5.
go back to reference International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM). Washington, DC: Health and Human Services Department, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, 2009 International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM). Washington, DC: Health and Human Services Department, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, 2009
7.
go back to reference Elixhauser A, Steiner CA, Whittington C. Clinical classifications for health policy research: hospital inpatient statistics, 1995 [online]. Healthcare Cost and Utilization Project, HCUP 3 Research Note. Rockville (MD): Agency for Health Care Policy and Research, 1998: AHCPR Pub. No. 98-0049. Available from URL: http://www.hcup-us.ahrq.gov/reports/natstats/his95.htm [Accessed 2009 Jun 19] Elixhauser A, Steiner CA, Whittington C. Clinical classifications for health policy research: hospital inpatient statistics, 1995 [online]. Healthcare Cost and Utilization Project, HCUP 3 Research Note. Rockville (MD): Agency for Health Care Policy and Research, 1998: AHCPR Pub. No. 98-0049. Available from URL: http://​www.​hcup-us.​ahrq.​gov/​reports/​natstats/​his95.​htm [Accessed 2009 Jun 19]
8.
go back to reference Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006 May 8; 166(9): 1021–6PubMedCrossRef Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006 May 8; 166(9): 1021–6PubMedCrossRef
11.
go back to reference Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008 Jun; 69(6): 889–98PubMedCrossRef Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008 Jun; 69(6): 889–98PubMedCrossRef
12.
go back to reference Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009 Feb; 8(2): 151–7PubMedCrossRef Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009 Feb; 8(2): 151–7PubMedCrossRef
13.
go back to reference Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuro-psychopharmacology 2008 Apr; 33(5): 1162–70CrossRef Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuro-psychopharmacology 2008 Apr; 33(5): 1162–70CrossRef
14.
go back to reference Elkashef A, Vocci F, Huestis M, et al. Marijuana neuro-biology and treatment. Subst Abuse 2008; 29(3): 17–29CrossRef Elkashef A, Vocci F, Huestis M, et al. Marijuana neuro-biology and treatment. Subst Abuse 2008; 29(3): 17–29CrossRef
15.
go back to reference Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006 Fall-Winter; 12(3–4): 178–207PubMedCrossRef Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006 Fall-Winter; 12(3–4): 178–207PubMedCrossRef
16.
go back to reference Nellissery M, Feinn RS, Covault J, et al. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res 2003 Sep; 27(9): 1402–8PubMedCrossRef Nellissery M, Feinn RS, Covault J, et al. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res 2003 Sep; 27(9): 1402–8PubMedCrossRef
17.
go back to reference Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000 Jul; 24(7): 1041–9PubMedCrossRef Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000 Jul; 24(7): 1041–9PubMedCrossRef
Metadata
Title
For What Diagnoses Are Psychotropic Medications Being Prescribed?
A Nationally Representative Survey of Physicians
Author
Dr Tami L. Mark
Publication date
01-04-2010
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11533120-000000000-00000

Other articles of this Issue 4/2010

CNS Drugs 4/2010 Go to the issue